Close Menu

NEW YORK – Personalis reported after the close of the market on Thursday that its third quarter revenues rose 16 percent year over year, driven largely by a 9 percent increase in revenues from the analytical services it provided to the US Department of Veterans Affairs Million Veteran Program (VA MVP).

On Friday, Oppenheimer downgraded the company's shares to a rating of Perform from Outperform, citing valuation, an expectation for headwinds from the COVID-19 pandemic on Personalis' pharma business, and a slowdown in growth from VA revenues.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The UK has given emergency authorization for Pfizer and BioNTech's SARS-CoV-2 vaccine, the Associated Press reports.

A US advisory committee says healthcare workers and nursing home residents should be prioritized to receive a SARS-CoV-2 vaccine, according to the Financial Times.

The Wall Street Journal reports North Korean hackers have targeted half a dozen companies developing SARS-CoV-2 vaccines.

In Cell this week: long-term SARS-CoV-2 shedding, examination of the effects of a coronavirus spike protein mutation, and more.